Literature DB >> 24264718

Mucopolysaccharidoses.

Rolando Cimaz1, Francesco La Torre.   

Abstract

The mucopolysaccharidoses (MPSs) are a group of rare genetic disorders of glycosaminoglycan catabolism, caused by a deficiency of lysosomal enzymes required for GAG degradation. Incomplete breakdown of glycosaminoglycans leads to progressive accumulation of these substances in many tissues throughout the body. Different residual enzymatic activity can result in different phenotypes of the same MPS disorder, from severe to attenuated. Musculoskeletal manifestations are common across all forms of MPS. Skeletal and joint abnormalities are prominent features of many MPS disorders, particularly attenuated phenotypes. However, diagnostic delays occur frequently for patients with an MPS, especially those with more attenuated forms of disease. In the absence of appropriate treatment, these conditions are chronic, progressive and often debilitating, but treatment for many types of MPS is now available. Therefore, increasing awareness of MPS among rheumatologists is extremely important.

Entities:  

Mesh:

Year:  2014        PMID: 24264718     DOI: 10.1007/s11926-013-0389-0

Source DB:  PubMed          Journal:  Curr Rheumatol Rep        ISSN: 1523-3774            Impact factor:   4.592


  84 in total

Review 1.  Musculoskeletal manifestations of mucopolysaccharidoses.

Authors:  Kimberly Morishita; Ross E Petty
Journal:  Rheumatology (Oxford)       Date:  2011-12       Impact factor: 7.580

2.  Spastic quadriparesis due to C1-C2 subluxation in Hurler syndrome.

Authors:  C B Brill; J S Rose; L Godmilow; S Sklower; J Willner; K Hirschhorn
Journal:  J Pediatr       Date:  1978-03       Impact factor: 4.406

3.  Spinal pachymeningitis secondary to mucopolysaccharidosis. Case report.

Authors:  G W Paulson; J N Meagher; J Burkhart
Journal:  J Neurosurg       Date:  1974-11       Impact factor: 5.115

4.  Carpal tunnel syndrome combined with trigger finger in early childhood.

Authors:  K Maurer; A Fenske; M Samii
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-12       Impact factor: 10.154

5.  Treatment of MPS VII (Sly disease) by allogeneic BMT in a female with homozygous A619V mutation.

Authors:  Y Yamada; K Kato; K Sukegawa; S Tomatsu; S Fukuda; S Emura; S Kojima; T Matsuyama; W S Sly; N Kondo; T Orii
Journal:  Bone Marrow Transplant       Date:  1998-03       Impact factor: 5.483

Review 6.  Carpal tunnel syndrome in children and adolescents with no history of trauma.

Authors:  M M al-Qattan; H G Thomson; H M Clarke
Journal:  J Hand Surg Br       Date:  1996-02

7.  Spinal problems in mucopolysaccharidosis I (Hurler syndrome).

Authors:  V Tandon; J B Williamson; R A Cowie; J E Wraith
Journal:  J Bone Joint Surg Br       Date:  1996-11

Review 8.  Mucopolysaccharidosis VI.

Authors:  Vassili Valayannopoulos; Helen Nicely; Paul Harmatz; Sean Turbeville
Journal:  Orphanet J Rare Dis       Date:  2010-04-12       Impact factor: 4.123

9.  Hurler syndrome with special reference to histologic abnormalities of the growth plate.

Authors:  C P Silveri; F S Kaplan; M D Fallon; E Bayever; C S August
Journal:  Clin Orthop Relat Res       Date:  1991-08       Impact factor: 4.176

10.  Long-term efficacy and safety of laronidase in the treatment of mucopolysaccharidosis I.

Authors:  Lorne A Clarke; J Edmond Wraith; Michael Beck; Edwin H Kolodny; Gregory M Pastores; Joseph Muenzer; David M Rapoport; Kenneth I Berger; Marisa Sidman; Emil D Kakkis; Gerald F Cox
Journal:  Pediatrics       Date:  2009-01       Impact factor: 7.124

View more
  11 in total

1.  Rare genetic diseases affecting skeletal development and oral health disparities among children and adolescents: a pathway analysis.

Authors:  Mario Vianna Vettore; Ana Cristina Borges-Oliveira; Heloisa Vieira Prado; Gabriela de Almeida Lamarca; Janine Owens
Journal:  Int Dent J       Date:  2020-07-17       Impact factor: 2.607

2.  Social/economic costs and health-related quality of life of mucopolysaccharidosis patients and their caregivers in Europe.

Authors:  Márta Péntek; László Gulácsi; Valentin Brodszky; Petra Baji; Imre Boncz; Gábor Pogány; Julio López-Bastida; Renata Linertová; Juan Oliva-Moreno; Pedro Serrano-Aguilar; Manuel Posada-de-la-Paz; Domenica Taruscio; Georgi Iskrov; Arrigo Schieppati; Johann Matthias Graf von der Schulenburg; Panos Kanavos; Karine Chevreul; Ulf Persson; Giovanni Fattore
Journal:  Eur J Health Econ       Date:  2016-04-09

3.  Arylsulfatase K inactivation causes mucopolysaccharidosis due to deficient glucuronate desulfation of heparan and chondroitin sulfate.

Authors:  Christof Trabszo; Bastian Ramms; Pradeep Chopra; Renate Lüllmann-Rauch; Stijn Stroobants; Jens Sproß; Anke Jeschke; Thorsten Schinke; Geert-Jan Boons; Jeffrey D Esko; Torben Lübke; Thomas Dierks
Journal:  Biochem J       Date:  2020-09-18       Impact factor: 3.857

Review 4.  Ocular manifestations and management recommendations of lysosomal storage disorders I: mucopolysaccharidoses.

Authors:  Carlton R Fenzl; Kyla Teramoto; Majid Moshirfar
Journal:  Clin Ophthalmol       Date:  2015-09-07

5.  Bull's eye maculopathy and subfoveal deposition in two mucopolysaccharidosis type I patients on long-term enzyme replacement therapy.

Authors:  Heather G Mack; R C Andrew Symons; Gerard de Jong
Journal:  Am J Ophthalmol Case Rep       Date:  2017-10-04

Review 6.  The role of imaging in the skeletal involvement of mucopolysaccharidoses.

Authors:  Vincenzo Spina; Domenico Barbuti; Alberto Gaeta; Stefano Palmucci; Ernesto Soscia; Marco Grimaldi; Antonio Leone; Renzo Manara; Gabriele Polonara
Journal:  Ital J Pediatr       Date:  2018-11-16       Impact factor: 2.638

7.  Recommendations for the management of MPS IVA: systematic evidence- and consensus-based guidance.

Authors:  Mehmet Umut Akyol; Tord D Alden; Hernan Amartino; Jane Ashworth; Kumar Belani; Kenneth I Berger; Andrea Borgo; Elizabeth Braunlin; Yoshikatsu Eto; Jeffrey I Gold; Andrea Jester; Simon A Jones; Cengiz Karsli; William Mackenzie; Diane Ruschel Marinho; Andrew McFadyen; Jim McGill; John J Mitchell; Joseph Muenzer; Torayuki Okuyama; Paul J Orchard; Bob Stevens; Sophie Thomas; Robert Walker; Robert Wynn; Roberto Giugliani; Paul Harmatz; Christian Hendriksz; Maurizio Scarpa
Journal:  Orphanet J Rare Dis       Date:  2019-06-13       Impact factor: 4.123

Review 8.  Mucopolysaccharidoses I and II: Brief Review of Therapeutic Options and Supportive/Palliative Therapies.

Authors:  Haiyan Nan; Chanbum Park; Sungho Maeng
Journal:  Biomed Res Int       Date:  2020-12-04       Impact factor: 3.411

9.  Diagnosis of Mucopolysaccharidosis Based on History and Clinical Features: Evidence from the Bajio Region of Mexico.

Authors:  Douglas Colmenares-Bonilla; Christian Colin-Gonzalez; Alejandra Gonzalez-Segoviano; Enrique Esquivel Garcia; Ma Martha Vela-Huerta; Fanny Guadalupe Lopez-Gomez
Journal:  Cureus       Date:  2018-11-20

10.  Mitral Valve Prolapse and Its Motley Crew-Syndromic Prevalence, Pathophysiology, and Progression of a Common Heart Condition.

Authors:  Jordan E Morningstar; Annah Nieman; Christina Wang; Tyler Beck; Andrew Harvey; Russell A Norris
Journal:  J Am Heart Assoc       Date:  2021-06-22       Impact factor: 5.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.